Erlotinib Completed Phase 2 Trials for Hepatocellular,Carcinoma / Liver Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00242502Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
NCT00287222Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00605722A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.